Genocea Biosciences (Genocea Biosciences) Quick Ratio : 1.35 (As of Mar. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Genocea Biosciences Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Genocea Biosciences's quick ratio for the quarter that ended in Mar. 2022 was 1.35.

Genocea Biosciences has a quick ratio of 1.35. It generally indicates good short-term financial strength.

The historical rank and industry rank for Genocea Biosciences's Quick Ratio or its related term are showing as below:

GNCAQ's Quick Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.51
* Ranked among companies with meaningful Quick Ratio only.

Genocea Biosciences Quick Ratio Historical Data

The historical data trend for Genocea Biosciences's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genocea Biosciences Quick Ratio Chart

Genocea Biosciences Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Quick Ratio

Get a 7-Day Free Trial

0.83

2.52

6.62

3.29

2.24

Genocea Biosciences Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Quick Ratio	Get a 7-Day Free Trial															6.02	4.24	3.44	2.24	1.35

Competitive Comparison of Genocea Biosciences's Quick Ratio

For the Biotechnology subindustry, Genocea Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genocea Biosciences's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genocea Biosciences's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Genocea Biosciences's Quick Ratio falls into.

Genocea Biosciences Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Genocea Biosciences's Quick Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Quick Ratio (A: Dec. 2021 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(41.822	-	0)	/	18.683
	=	2.24

Genocea Biosciences's Quick Ratio for the quarter that ended in Mar. 2022 is calculated as

Quick Ratio (Q: Mar. 2022 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(24.408	-	0)	/	18.03
	=	1.35

Genocea Biosciences (OTCPK:GNCAQ) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.

Genocea Biosciences Quick Ratio Related Terms

Thank you for viewing the detailed overview of Genocea Biosciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Genocea Biosciences (Genocea Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genocea Biosciences Inc (OTCPK:GNCAQ) » Definitions » Quick Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Acorn Park Drive, Cambridge, MA, USA, 02140

Website

https://www.genocea.com

Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.

Executives

Jacquelyn L Sumer	officer: CHIEF LEGAL & COMPLIANCE OFF	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
William D Clark	director, officer: President and CEO	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
George Siber	director	2000 BROADWAY, PENTHOUSE 2B, NEW YORK NY 10023
Diantha Duvall	officer: CHIEF FINANCIAL OFFICER	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Scott D Sandell	10 percent owner
Stapleton Raymond D Jr	officer: EVP PHARM SCI & MFG	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jessica Baker Flechtner	officer: VP of Research	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Ali Behbahani	director	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Forest Baskett	10 percent owner
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815